Special Issue "Novel Multifunctional Ligands and Their Application in Alzheimer's Disease"
Deadline for manuscript submissions: 20 May 2018
Prof. Dr. Praveen P. Nekkar Rao
School of Pharmacy, Health Sciences Campus, University of Waterloo, 200 University Avenue West, Waterloo N2L 3G1, Canada
Website | E-Mail
Phone: 519-888-4567 ext: 21317
Interests: medicinal chemistry; Alzheimer’s disease; drug discovery; structure-based design; organic synthesis; protein–protein interactions; protein–small molecule interactions
More than 100 years ago, the German psychiatrist Alois Alzheimer described an unusual disease in one of his patient’s which was later called Alzheimer’s disease (AD). Since then, humanity has seen an exponential growth in both basic and applied sciences, which has led to the successful treatment of a number of diseases. Despite these advances, unfortunately, cholinesterase inhibitors, which only provide symptomatic relief remain the major class of drugs used in the pharmacotherapy of AD. Nearly 47 million people are affected with AD or related dementia (Alzheimer’s Association, USA). These numbers are expected to grow in the coming years, burdening the health, social, and economic landscape of many countries across the globe. These facts mandate an urgent need to discover novel treatment options for AD. On this note, recent focus has been on designing hybrid multifunctional ligands as disease modifying agents capable of providing not only symptomatic relief but more significantly, prevent disease progression and potentially cure AD. This Special Issue is a call for academic and industrial scientists to share their research on their discovery efforts toward multifunctional ligands aimed at AD. The scope of this issue includes natural/synthetic small molecules, peptides, computational design and lead optimization.
Prof. Dr. Praveen P. Nekkar Rao
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Beta amyloid
- tau protein
- mitochondrial dysfunction
- oxidative stress
- computational methods